SIRT3 deacetylates IDH2 at K413, which activates its enzymatic activity by promoting IDH2 dimer formation, subsequently reducing intracellular ROS and glycolysis, and inhibiting the tumour‐prone phenotype.260, 261, 262. Here, SIRT3 is linked to neoplasm.